Our History


In December of 2013, two co-founders residing in CT joined together, establishing Tangen Biosciences, each bringing extensive industry experience developing and commercializing gene synthesis platform and next-generation sequencing technologies.

When founding Tangen, their goal was to get high-quality molecular diagnostics for infectious diseases out of the laboratory and closer to the patient, including remote, rural, and underserved communities. They developed the initial instrument prototype in the basement of one of the co-founders’ homes in Guilford, Connecticut. The company has experienced fast growth in the last several years and has grown to over 50 employees today in a 16,000 square foot office, lab, and clean room manufacturing facility.

  • BARDA awarded the Third Phase of the Anthrax contract
  • BARDA awarded a point-of-care COVID-19 molecular assay development contract
  • NYS Wadsworth Center/HRI awarded a point-of-care Candida auris assay development contract
  • Completed $12.2MM Series B financing round
  • Formed exclusive partnership with LabWare, Inc.
  • Completed $9MM Series A equity financing
  • BARDA awarded the Second Phase of the Anthrax contract
  • Moved to a 16,000 square foot GMP manufacturing facility

Richard Birkmeyer was appointed as

Tangen’s President and CEO


BARDA awarded a contract to Tangen to detect Anthrax directly from blood

  • Developed TangenDx – fungal sepsis panel
  • Awarded a Phase I SBIR grant from the NIH

Completed $2MM Seed Round equity financing


Developing GeneSpark – A portable, rapid and easy-to-use molecular diagnostic platform


The Company was founded